Scarica l'app Stockscreener
32.73
5.68%
1.76
Pre-mercato:
32.97
0.24
+0.73%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$30.97
Aprire:
$30.98
Volume 24 ore:
8.21M
Relative Volume:
0.79
Capitalizzazione di mercato:
$12.66B
Reddito:
$3.14B
Utile/perdita netta:
$-3.36B
Rapporto P/E:
-3.7491
EPS:
-8.73
Flusso di cassa netto:
$-4.03B
1 W Prestazione:
+3.64%
1M Prestazione:
+26.37%
6M Prestazione:
-14.99%
1 anno Prestazione:
-73.28%
Intervallo 1D:
$30.98
$32.84
Intervallo di 1 settimana:
$30.88
$32.84
Portata 52W:
$23.15
$125.68
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Confronta MRNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
32.73 | 12.21B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
Melanoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Algorithm, Pipeline Analysis | IO Biotech, Moderna Inc., Merck Sharp & Dohme LLC, BioNTech SE, TILT Biotherapeutics LLC, Nykode - Barchart.com
South Dakota Investment Council Lowers Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna (NASDAQ:MRNA) Given New $25.00 Price Target at Bank of America - MarketBeat
What analysts say about Moderna Inc. stockHigh-velocity gains - jammulinksnews.com
Moderna Inc. Stock Analysis and ForecastRapid profit acceleration - jammulinksnews.com
Moderna Target of Unusually High Options Trading (NASDAQ:MRNA) - MarketBeat
New York State Common Retirement Fund Sells 33,365 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
What drives Moderna Inc. stock pricePowerful growth strategies - Autocar Professional
Lexicography: Clear And Unequivocal - The National Law Review
Wealthfront Advisers LLC Purchases 18,268 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
After Moderna Pulled Its Shot, Combination Flu/COVID Vaccines Hang in Limbo - BioSpace
Moderna Bets Big On New Vaccines After Stock Tumbles - Finimize
Equities Analysts Offer Predictions for Moderna Q2 Earnings - MarketBeat
Is Moderna Inc. a good long term investmentRobust investment performance - jammulinksnews.com
Edgestream Partners L.P. Has $2.78 Million Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
OVERSEA CHINESE BANKING Corp Ltd Buys 17,268 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Shares Acquired by Nisa Investment Advisors LLC - MarketBeat
Moderna, Inc. (MRNA) Aktienkurs, Nachrichten, Kurs und Verlauf - yahoo.co
Here's Why Moderna (MRNA) Fell More Than Broader Market - Yahoo Finance
Moderna, Lantheus, Centene, AMN Healthcare Services, and NeoGenomics Shares Plummet, What You Need To Know - Yahoo Finance
How IBM and Moderna’s partnership could lead to an explosion in drug development - Fast Company
Moderna cancels plans to build Japan plant on poor business environment - Reuters
Moderna gets full FDA approval for kids COVID-19 vaccine - MSN
Moderna, Inc.'s (NASDAQ:MRNA) Price Is Right But Growth Is Lacking After Shares Rocket 26% - simplywall.st
Moderna cancels mRNA production plant in Japan (MRNA:NASDAQ) - Seeking Alpha
Cwm LLC Purchases 28,831 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Lobbying Update: $120,000 of MODERNA INC. lobbying was just disclosed - Quiver Quantitative
Thursday's Notable Option Activity: Oracle, United Airlines, Moderna - AInvest
How IBM and Moderna (MRNA) Are Using Quantum Computing to Design Vaccines Faster - TipRanks
Moderna to Report Second Quarter 2025 Financial Results on Friday, August 1, 2025 - Amarillo Globe-News
Moderna Receives Full U.S. FDA Approval for COVID-19 Vaccine, Spikevax, in Children Aged 6 Months Through 11 Years at Increased Risk for COVID-19 Disease - Knoxville News Sentinel
IBM-Moderna Showcase Quantum-Enhanced Drug Discovery - HPCwire
IBM and Moderna Team Up on Quantum Study. What It Means for the World of Medicine. - Barron's
Director, Strategic Forecasting, Oncology job with Moderna, Inc. | 1402245670 - New Scientist
Moderna’s latest approval again reveals FDA rift over COVID vaccines - BioPharma Dive
Bank of New York Mellon Corp Purchases 34,034 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
FDA Fully Approves Moderna’s COVID-19 Vaccine for Some Young Children - Vaccine Advisor
Lobbying Update: $100,000 of MODERNA US INC. lobbying was just disclosed - Quiver Quantitative
Moderna patent for mRNA vaccine knocked back, for now - Lawyerly
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):